Vaping Cessation: Achieve Life Sciences Announces Positive Phase 2 ORCA--V1 Trial Results | Pharmacy Podcast Nation

An estimated 28.3 million adults in the United States currently smoke cigarettes.  More than 16 million Americans live with a smoking-related disease. 1 in 20 Americans vape, and teenage e-cigarette consumption has increased by 1,800% over the last year. 14.1% (2.14 million) of high school students and 3.3% (380,000) of middle school students reported current e-cigarette use. John Bencich is the CEO of Achieve Life Sciences.  Achieve Life Sciences, Inc. a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, reported positive topline results from its Phase 2 ORCA-V1 trial. ORCA-V1 evaluated the efficacy and safety of 3mg cytisinicline dosed three times daily for 12 weeks compared to placebo in 160 adults who use e-cigarettes or nicotine vapes and who do not currently smoke cigarettes. All participants received behavioral support for nicotine cessation.